Skip to main content
. 2022 Sep 12;17(9):e0274519. doi: 10.1371/journal.pone.0274519

Fig 2. Forest plot of association between sodium-glucose cotransporter 2 (SGLT2) inhibitor use and hepatocellular carcinoma mortality by covariates (- Numbers have been suppressed to protect confidentiality).

Fig 2